What's Hot
View all perspectives
Pedro Castillo _Castillo_Pedro
3 years 1 month ago
Dr. Dellaripa w/great talk on digital ischemia.
Presents case of 25 yo F w/SLE, Class IV LN, APS, on apixaban, MMF, HCQ admitted w/AKI, ⬆️Upro & U-blood
-> new HFrEF (EF 22%), tachy, & digital ischemia w/skin bx = thrombotic vasculopathy.
#ACR21 Scientific Session 9T114 @RheumNow
Pedro Castillo _Castillo_Pedro
3 years 1 month ago
Had a blast with the @RheumNow team covering #ACR21! Eager to pour over more material over the coming weeks. What did folks do before the abstracts and videos were available online??
Md Yuzaiful Md Yusof Yuz6Yusof
3 years 1 month ago
Third Time's the Charm - COVID Vaccination While on Rituximab: Dr. Yuz Y... https://t.co/uxA00n1hxy via @YouTube Do watch my short commentary on the enhanced immuno-protection of 3rd primary #COVID dose in patients who are treated with rituximab #ACR21 @RheumNow
Md Yuzaiful Md Yusof Yuz6Yusof
3 years 1 month ago
Risk of retinopathy vs #lupus flares. Do watch my interview with Dr Jorge on her works on issues surrounding hydroxyxhloroquine dose #ACR21 @RheumNow https://t.co/hKsAi4dD2n
Mrinalini Dey DrMiniDey
3 years 1 month ago
Watch the @RheumNow #rheumatoidarthritis panel discuss some of our highlights from #ACR21!
https://t.co/Q5Yps3s165
Md Yuzaiful Md Yusof Yuz6Yusof
3 years 1 month ago
Do watch the Autoinflammatory Faculty @RheumNow discussed a selection of data presented at #ACR21 @uptoTate @bella_mehta @DrPetryna
Autoinflammatory: PAH in AOSD, VEXAS, JAKi in Still's, Role of labs in i... https://t.co/4biuKzWLBc via @YouTube
Jeffrey Sparks MD MMSc jeffsparks
3 years 1 month ago
Impromptu #TeamSparks video meeting with 2nd year fellows @KronzerMD and Dr Gregory McDermott detailing our research findings from the @MassGenBrigham Biobank (funded by @NIH_NIAMS and VERITY) @OrACORe_BWH @MayoClinic @RheumNow #ACR21
https://t.co/CQ9XDamb0E
David Liew drdavidliew
3 years 1 month ago
So I think the talk of #ACR21 has been ORAL Surveillance, the phase 3b/4 @US_FDA post-marketing requirement study of tofacitinib vs TNFi in CV risk pts.
I've tried to capture this live through a few threads/tweets, as it happened.
Catch up via this thread of threads @RheumNow
Dr. John Cush RheumNow
3 years 1 month ago
Dr. Aurelie Nahm ( @AurelieRheumo) shares #ACR21 presentation findings on TNF inhibitors and radiographic progression in axSpA
https://t.co/FPs43SGH5R https://t.co/MeM1Js5p4n
Dr. John Cush RheumNow
3 years 1 month ago
Sinusitis and Pharyngitis with Incident RA: Dr. Richard Conway discusses abstract #0564 presented at the #ACR21 annual meeting.
https://t.co/rWS8VT5obl https://t.co/cHLTf9HPWe
Dr. John Cush RheumNow
3 years 1 month ago
RheumNow’s expanded coverage of the #ACR21 Annual meeting is sponsored in part by @bmsnews, @JanssenUS, @Novartis. All content chosen by RheumNow & its Faculty.
Robert B Chao, MD doctorRBC
3 years 1 month ago
Drug retention of TNFi vs. secukinumab in AxSpA pts
Abs#911
⭐️46% discontinued either treatment
⭐️TNFi with slightly better drug retention
⭐️Age, BASDAI, BMI did not favor any group
⭐️inefficacy - main reason
#ACR21 @RheumNow https://t.co/ynoomYrTvX
Guy Katz, MD GuyKatzMD
3 years 1 month ago
📢No difference in ESRD or mortality with RTX-based vs CYC-based induction regimen in ANCA #Vasculitis
#ACR21 https://t.co/Bdz5t2uyHi
EnvisionRheumat ERheumat
3 years 1 month ago
#ACR21 #ACR2021
Extra pulmonary sarcoidosis ➡️ Cutaneous Sarcoidosis
👌🏻 talk
not posting a tweetorial for the talk as I would suggest go see the talk once
masterclass in Cutaneous sarcoidosis https://t.co/vkWXkq7DXF
Poster Hall